Brokerages predict that West Pharmaceutical Services (NYSE:WST) will report $0.65 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for West Pharmaceutical Services’ earnings. The highest EPS estimate is $0.66 and the lowest is $0.64. West Pharmaceutical Services posted earnings per share of $0.60 in the same quarter last year, which would suggest a positive year over year growth rate of 8.3%. The business is expected to announce its next earnings report on Thursday, April 26th.
On average, analysts expect that West Pharmaceutical Services will report full-year earnings of $2.85 per share for the current year, with EPS estimates ranging from $2.80 to $2.90. For the next fiscal year, analysts anticipate that the company will post earnings of $3.24 per share, with EPS estimates ranging from $3.06 to $3.40. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow West Pharmaceutical Services.
West Pharmaceutical Services (NYSE:WST) last issued its earnings results on Thursday, February 15th. The medical instruments supplier reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. The company had revenue of $415.60 million during the quarter, compared to analysts’ expectations of $416.90 million. West Pharmaceutical Services had a return on equity of 14.68% and a net margin of 9.42%. West Pharmaceutical Services’s quarterly revenue was up 8.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.54 EPS.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Comerica Bank lifted its holdings in West Pharmaceutical Services by 0.9% in the 4th quarter. Comerica Bank now owns 62,742 shares of the medical instruments supplier’s stock worth $6,293,000 after buying an additional 585 shares during the period. Paloma Partners Management Co lifted its holdings in West Pharmaceutical Services by 17.5% in the 4th quarter. Paloma Partners Management Co now owns 4,424 shares of the medical instruments supplier’s stock worth $437,000 after buying an additional 659 shares during the period. Amalgamated Bank lifted its holdings in West Pharmaceutical Services by 5.5% in the 4th quarter. Amalgamated Bank now owns 15,408 shares of the medical instruments supplier’s stock worth $1,520,000 after buying an additional 803 shares during the period. Cambridge Trust Co. lifted its holdings in West Pharmaceutical Services by 7.0% in the 4th quarter. Cambridge Trust Co. now owns 12,421 shares of the medical instruments supplier’s stock worth $1,226,000 after buying an additional 817 shares during the period. Finally, Jane Street Group LLC lifted its holdings in West Pharmaceutical Services by 16.8% in the 4th quarter. Jane Street Group LLC now owns 6,307 shares of the medical instruments supplier’s stock worth $622,000 after buying an additional 907 shares during the period. Institutional investors and hedge funds own 94.39% of the company’s stock.
WST stock traded down $1.70 during trading on Friday, hitting $83.32. 395,313 shares of the company traded hands, compared to its average volume of 412,093. The stock has a market capitalization of $6,355.44, a PE ratio of 29.93, a P/E/G ratio of 2.20 and a beta of 1.11. West Pharmaceutical Services has a 1 year low of $77.97 and a 1 year high of $103.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 2.66 and a quick ratio of 1.89.
West Pharmaceutical Services announced that its board has authorized a stock repurchase program on Thursday, February 15th that allows the company to repurchase 800,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 2nd. Shareholders of record on Wednesday, April 18th will be issued a $0.14 dividend. This represents a $0.56 annualized dividend and a yield of 0.67%. The ex-dividend date of this dividend is Tuesday, April 17th. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 20.14%.
COPYRIGHT VIOLATION NOTICE: This article was reported by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.tickerreport.com/banking-finance/3336374/zacks-analysts-expect-west-pharmaceutical-services-wst-will-announce-earnings-of-0-65-per-share.html.
West Pharmaceutical Services Company Profile
West Pharmaceutical Services, Inc manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.